- Conditions
- Type 2 Diabetes
- Interventions
- AZD0186, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Glendale, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 39
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Upper Endoscopy, GLP1-R-related Disease
- Interventions
- Modified Fasting Guidelines
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Osteoporosis, Postmenopausal, Diabetes Mellitus, Type 2
- Interventions
- GLP-1 receptor agonist
- Drug
- Lead sponsor
- University of Mississippi Medical Center
- Other
- Eligibility
- 55 Years and older · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Jackson, Mississippi
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- GLP-1 receptor agonist, Insulin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes
- Interventions
- Epic-Based Clinician Notification, Usual Care
- Other
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Plano, Texas
- Conditions
- HIV, Alcohol, Smoking Cigarette, Cardiovascular Disease Prevention
- Interventions
- Semaglutide (Rybelsus®), Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Overweight or Obesity
- Interventions
- None - Observational study
- Other
- Lead sponsor
- American Heart Association
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2060
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Aging, Diabetes Mellitus, Type 2, PreDiabetes, Overweight and Obesity
- Interventions
- Semaglutide Injectable Product, Lifestyle Counseling
- Drug · Behavioral
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 65 Years to 90 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Obesity, Diabetes Type 2
- Interventions
- Semaglutide Pen Injector [Ozempic]
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Lancaster, Pennsylvania
- Conditions
- Type 2 Diabetes
- Interventions
- Exenatide Injection (before the first FSIGT), Exenatide injection before the second FSIGT)
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Lancaster, Pennsylvania
- Conditions
- Healthy Volunteers (HV)
- Interventions
- Investigational Drug: IBI3042, Matching Placebo
- Drug
- Lead sponsor
- Fortvita Biologics (USA)Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Pulmonary Aspiration
- Interventions
- Gastric ultrasound
- Diagnostic Test
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Obesity/Therapy
- Interventions
- Semaglutide 1.7mg subcutaneous, Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 12 Years to 45 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Obesity Prevention, Obesity Recidivism, GLP-1, Ablation Techniques
- Interventions
- Gastric Fundal Mucosal Ablation (GFMA)
- Device
- Lead sponsor
- Dr. Christopher McGowan
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Cary, North Carolina
- Conditions
- Weight Maintenance
- Interventions
- Digital Behavioral Application
- Behavioral
- Lead sponsor
- Tufts University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Gastric Emptying, Glucagon-Like Peptide-1 Receptor Agonists, Intermittent Fasting, Intraoperative Complication Due to Anesthesia, Respiratory Aspiration of Gastric Contents
- Interventions
- Ultrasound of gastric contents
- Diagnostic Test
- Lead sponsor
- Wael Saasouh, MD
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- Semaglutide (Rybelsus®), Placebo
- Drug · Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Dietary Change, Obesity & Overweight, Food Acceptance
- Interventions
- Pistachios, Dual-energy X-ray absorptiometry (DEXA) scans
- Dietary Supplement · Procedure
- Lead sponsor
- Ian J. Neeland, MD
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Clevland, Ohio
- Conditions
- Obesity or Overweight
- Interventions
- Maridebart Cafraglutide
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 44
- States / cities
- Pelham, Alabama • Chandler, Arizona • Sun City, Arizona + 38 more
- Conditions
- glp1 Agonist, Gene Expression, Skin Laxity
- Interventions
- ellacor
- Device
- Lead sponsor
- Cytrellis Biosystems, Inc.
- Industry
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Dublin, California
- Conditions
- Dietary Change, Obesity & Overweight, Food Acceptance
- Interventions
- Peanuts, Dual-energy X-ray absorptiometry (DEXA) scans
- Dietary Supplement · Procedure
- Lead sponsor
- Ian J. Neeland, MD
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Clevland, Ohio
- Conditions
- Type 2 Diabetes (T2DM)
- Interventions
- SGLT-2 inhibitor, GLP1-RA
- Drug
- Lead sponsor
- MaryAnn Banerji
- Other
- Eligibility
- 24 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Obesity & Overweight, Cardiometabolic Health Indicators, Addiction, Eating Disorders, Mental Health
- Interventions
- GLP-1 Receptor Agonist Therapy, Structured Lifestyle Intervention
- Drug · Behavioral
- Lead sponsor
- Texas Tech University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Lubbock, Texas
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- MEDI0382 Formulation 2, MEDI0382 Formulation 3
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Dallas, Texas